Special Issue

Advances in Novel Drug Discovery, Synthesis, and Evaluation

Message from the Guest Editor

The Special Issue titled "Advances in Novel Drug Discovery, Synthesis, and Evaluation" focuses on the latest developments in drug development, highlighting new strategies and methods for synthesizing and evaluating therapeutic agents for a wide range of diseases. As we confront diverse health challenges, including infectious diseases, cancer, and neurodegenerative disorders, the demand for innovative solutions is more critical than ever. This Special Issue invites contributions that explore practical techniques in medicinal chemistry, such as structure-based drug design, and advancements in synthetic methodologies that enhance the efficiency of drug development. Additionally, contributions on computational modeling, artificial intelligence, and high-throughput screening are encouraged, as these tools play essential roles in streamlining the drug discovery process and optimizing candidate selection. We welcome original research articles, comprehensive reviews, and insightful case studies that discuss the current challenges in the field while offering promising advancements and future directions.

Guest Editor

Dr. Khaled M. Elokely

Division of Pharmaceutical Sciences, School of Pharmacy, College of Health Sciences, University of Wyoming, Laramie, WY 82071, USA

Deadline for manuscript submissions

30 April 2025

MDPI

Biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).